Onsdag 9 September | 11:41:58 Europe / Stockholm
Est. tid*
2027-03-09 08:00 Kvartalsrapport 2027-Q2
2026-11-05 N/A Årsstämma
2026-09-16 08:00 Bokslutskommuniké 2026
2026-03-05 - Kvartalsrapport 2026-Q2
2025-11-07 - X-dag ordinarie utdelning HEALTH 0.00 EUR
2025-11-06 - Årsstämma
2025-09-18 - Bokslutskommuniké 2025
2025-03-06 - Kvartalsrapport 2025-Q2
2024-11-11 - X-dag ordinarie utdelning HEALTH 0.00 EUR
2024-11-08 - Årsstämma
2024-09-20 - Bokslutskommuniké 2024
2024-03-07 - Kvartalsrapport 2024-Q2
2023-11-17 - X-dag ordinarie utdelning HEALTH 0.00 EUR
2023-11-16 - Årsstämma
2023-09-28 - Bokslutskommuniké 2023
2023-04-24 - Extra Bolagsstämma 2023
2023-03-23 - Kvartalsrapport 2023-Q2
2022-11-17 - Årsstämma
2022-10-25 - X-dag ordinarie utdelning HEALTH 0.00 EUR
2022-09-29 - Bokslutskommuniké 2022
2022-06-29 - Extra Bolagsstämma 2022
2022-02-24 - Kvartalsrapport 2022-Q2
2021-10-29 - X-dag ordinarie utdelning HEALTH 0.00 EUR
2021-10-28 - Årsstämma
2021-09-15 - Bokslutskommuniké 2021
LandFinland
ListaSmall Cap Helsinki
SektorHälsovård
IndustriMedicinteknik
Nightingale Health är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar plattformar och tjänster inom blodanalyser som används i sjukdomsförebyggande syfte. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs globalt med störst närvaro i Europa.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Nightingale Health and Genom partner to bring blood-based risk detection to clinics and laboratories across Croatia

2026-09-09 09:30:00

Nightingale Health Plc | Press Release | September 09, 2026 at 10:30:00 EEST

Nightingale Health and Genom have formed a partnership to make the Nightingale Health Check available through Genom's network of clinics and laboratories across Croatia. Under the partnership, Genom offers the test to the healthcare providers in its network and Nightingale Health analyses the blood samples. The agreement marks Nightingale Health's entry into the Croatian market and follows three completed pilots, with demand already established among both clinics and laboratories.

Under the partnership, Genom will offer the Nightingale Health Check to the clinics and laboratories in its network, and Nightingale Health will analyse the blood samples. From a single blood sample, the Nightingale Health Check produces a 10-year risk estimate for five chronic diseases: heart attack, ischemic stroke, type 2 diabetes, chronic kidney disease, and fatty liver disease. Healthcare providers in Genom's network can offer the test to the people they serve, who receive their results through their own clinic or laboratory. Clinicians make all clinical decisions under existing medical guidelines; the test helps identify earlier who would benefit most from preventive action.

Genom is an established Croatian biotechnology company that works through a network of partner clinics, laboratories and medical practices across the country. The partnership adds blood-based chronic-disease risk detection to the services Genom can offer through that network. Three pilots have already been completed, and interest has come from both clinics and laboratories. The companies plan to roll out the Nightingale Health Check across Genom's network later in 2026, with the aim of reaching nationwide use.

“Our goal has always been to make innovative healthcare solutions accessible through trusted healthcare providers. The Nightingale Health Check complements our existing portfolio by providing healthcare professionals with a scientifically validated tool for earlier identification of chronic disease risk and more personalized preventive care,” says Maja Barbalić, CEO and Founder of Genom.

“Genom gives us an established route into Croatian healthcare, with a network of clinics and laboratories that are ready to use the Nightingale Health Check. Three completed pilots and demand from both clinics and laboratories show that the market is positive about our test. With a partner of Genom's standing and reach, we have a strong foundation to build on in Croatia,” says Teemu Suna, CEO and Founder of Nightingale Health.

About Genom

Genom is a Croatian biotechnology company based in Zagreb that brings innovative genetic and molecular testing solutions to healthcare providers through a network of partner clinics, laboratories and medical practices across Croatia. With more than a decade of experience, Genom focuses on making advanced diagnostics accessible, supported by a scientific team of molecular biologists and geneticists. Read more: https://genom.hr/

For Genom enquiries: info@genom.hr